Through tumor-forming assay in which phenotypically diverse cells were separately transplanted into immunodeficient mice, CSC was first “identified” in human acute myeloid leukemia (AML) since only CD34+CD38− cells were found to have the ability of tumor initiation, self-renewal, and generating cells of other subsets under such condition [14]. Here, CD34 is linked to neoplasm.